ARQT vs. RVMD, GRFS, RYTM, LEGN, ABVX, RNA, CYTK, AXSM, NUVL, and TGTX
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
Arcutis Biotherapeutics vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.
94.3% of Revolution Medicines shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Revolution Medicines has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -35.40%. Revolution Medicines' return on equity of -41.78% beat Arcutis Biotherapeutics' return on equity.
Revolution Medicines currently has a consensus target price of $73.67, suggesting a potential upside of 65.58%. Arcutis Biotherapeutics has a consensus target price of $19.80, suggesting a potential upside of 12.79%. Given Revolution Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe Revolution Medicines is more favorable than Arcutis Biotherapeutics.
Revolution Medicines has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.
In the previous week, Revolution Medicines had 14 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 20 mentions for Revolution Medicines and 6 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.01 beat Revolution Medicines' score of 0.53 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Arcutis Biotherapeutics has higher revenue and earnings than Revolution Medicines. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
Revolution Medicines beats Arcutis Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARQT) was last updated on 9/22/2025 by MarketBeat.com Staff
